Difficulty: Medium
Average Score: 73%
Practice
This drug is the antimalarial agent most commonly associated with causing an acute hemolytic reaction in patients with glucose - 6 - phosphate dehydrogenase deficiency.
Correct answer
D
Rationale
In this scenario, the correct answer is D) Primaquine. Primaquine is an antimalarial drug known to cause acute hemolytic reactions in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is an inherited condition that affects the red blood cells, leading to hemolysis when exposed to certain triggers like primaquine.
Option A) Chloroquine is an antimalarial drug but is not commonly associated with hemolytic reactions in G6PD deficient individuals.
Option B) Clindamycin is an antibiotic and not an antimalarial drug, so it is not relevant to this scenario.
Option C) Mefloquine is another antimalarial drug, but it is not as strongly associated with hemolytic reactions in G6PD deficient patients compared to primaquine.
Educationally, understanding the potential adverse effects of different chemotherapy drugs, including antimalarials like primaquine, is crucial for healthcare professionals to ensure safe and effective treatment for patients. Recognizing the specific risks associated with certain drugs in different patient populations, such as those with G6PD deficiency, is essential for providing high-quality care and avoiding complications.
Option A) Chloroquine is an antimalarial drug but is not commonly associated with hemolytic reactions in G6PD deficient individuals.
Option B) Clindamycin is an antibiotic and not an antimalarial drug, so it is not relevant to this scenario.
Option C) Mefloquine is another antimalarial drug, but it is not as strongly associated with hemolytic reactions in G6PD deficient patients compared to primaquine.
Educationally, understanding the potential adverse effects of different chemotherapy drugs, including antimalarials like primaquine, is crucial for healthcare professionals to ensure safe and effective treatment for patients. Recognizing the specific risks associated with certain drugs in different patient populations, such as those with G6PD deficiency, is essential for providing high-quality care and avoiding complications.